• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/17/25 4:50:32 PM ET
    $PROK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PROK alert in real time by email
    8-K
    0001850270false00018502702025-03-172025-03-17

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 17, 2025

     

     

    PROKIDNEY CORP.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Cayman Islands

    001-40560

    98-1586514

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2000 Frontis Plaza Blvd.

    Suite 250

     

    Winston-Salem, North Carolina

     

    27103

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 336 999-7019

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A ordinary shares, $0.0001 par value per share

     

    PROK

     

    The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On March 17, 2025, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1.

    The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

     

    Exhibit No.

    Description

    99.1

    Press Release dated March 17, 2025

    104

    Cover Page Interactive Data File (embedded within Inline XBRL document)

    
     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    PROKIDNEY CORP.

     

     

     

     

    Date:

    March 17, 2025

    By:

    /s/ James Coulston

     

     

     

    James Coulston
    Chief Financial Officer

     

     


    Get the next $PROK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROK

    DatePrice TargetRatingAnalyst
    9/30/2024Neutral
    JP Morgan
    9/10/2024$6.00Buy
    Guggenheim
    3/7/2024$3.00Equal-Weight
    Morgan Stanley
    1/2/2024Buy → Neutral
    BofA Securities
    7/25/2023$16.00Buy
    BTIG Research
    12/21/2022$15.00Buy
    Jefferies
    11/10/2022$13.00Equal-Weight
    Morgan Stanley
    10/18/2022$18.00Buy
    UBS
    More analyst ratings

    $PROK
    Financials

    Live finance-specific insights

    See more
    • ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

      Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trialsManagement to host live webcast today at 8:00 a.m. ET WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) --  ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced positive interim results from the Phase 2 REGEN-007 trial evaluating the Company's renal autologous cell therapy, rilparencel, in patients with CKD caused by diabetes and provided clinical

      6/10/24 6:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Third Quarter Financial Results

      WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023. "Building off of our positive corporate update, and with nearly $400 million in cash, cash equivalents and marketable securities as of September 30th of this year, ProKidney continues to be well capitalized to continue executing on both of our Phase 2 and Phase 3 trials in high-risk CKD patients in need," said James Coulston, Chief Financial Officer at ProKidney. "With cash expected to fund operations into the

      11/14/23 6:05:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

      Updated positive interim Phase 2 data demonstrate potential efficacy of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients Focusing Phase 3 development program on patients with Stage 3b and 4 diabetic CKD at highest risk of advancing to kidney failure and need for renal replacement therapy Dr. Bruce Culleton appointed ProKidney CEO following Dr. Tim Bertram's transition to advisory role Sufficient capital to fund operations into fourth quarter 2025 ProKidney to host conference call and webcast tomorrow at 8:00 a.m. ET WINSTON-SALEM, N.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a leading late clinical-stage cellu

      11/13/23 5:02:13 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ProKidney Corp.

      SCHEDULE 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      5/6/25 3:45:08 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by ProKidney Corp.

      EFFECT - PROKIDNEY CORP. (0001850270) (Filer)

      4/29/25 12:15:06 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by ProKidney Corp.

      424B3 - PROKIDNEY CORP. (0001850270) (Filer)

      4/28/25 4:51:14 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan initiated coverage on ProKidney Corp.

      JP Morgan initiated coverage of ProKidney Corp. with a rating of Neutral

      9/30/24 7:50:41 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on ProKidney Corp. with a new price target

      Guggenheim initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $6.00

      9/10/24 7:56:11 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on ProKidney Corp. with a new price target

      Morgan Stanley resumed coverage of ProKidney Corp. with a rating of Equal-Weight and set a new price target of $3.00

      3/7/24 7:33:04 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      11/8/24 10:13:46 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ProKidney Corp.

      SC 13G/A - PROKIDNEY CORP. (0001850270) (Subject)

      10/22/24 3:32:15 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ProKidney Corp.

      SC 13D/A - PROKIDNEY CORP. (0001850270) (Subject)

      6/25/24 4:08:10 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProKidney Reports Full Year 2024 Financial Results and Business Highlights

      Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway into mid-2027In Q4 2024, the FDA confirmed in a Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, which may include eGFR slope, is used; additional details expected in mid-2025Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025; interim data from June 2024 showed kidney function stabilization for 18 months in patients with advanced CKD and diabetesEnd

      3/17/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 43rd Annual J.P. Morgan Healthcare ConferenceDate:January 15, 2025Time:7:30am PSTFormat:PresentationWebcast:Link   The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website

      1/7/25 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference

      WINSTON-SALEM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in December: Evercore HealthCONx ConferenceDate:December 3, 2024Time:8:45am ETFormat:Fireside ChatWebcast:Link  Citi Global Healthcare ConferenceDate:December 4, 2024Format:One-on-one meetings   The live webcast for the Evercore fireside chat will be accessible through the "Events" section of the Investor Relations tab w

      11/26/24 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Leadership Updates

    Live Leadership Updates

    See more
    • ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.

      Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company's highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and focused Company resources on PROACT 1 to expedite enrollment and accelerate estimated topline data readout to Q3 2027 WINSTON-SALEM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced strategic updates to its Phase 3 program for rilparencel, an investigational treatment to potentiall

      9/3/24 7:30:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Business Updates and First Quarter 2024 Financial Results

      Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD with Dr. Arnold Silva and Dr. Steven Coca and a recap of the RMCL-002 data is planned for May 28, 2024On schedule to resume manufacturing and PROACT 1 Phase 3 trial, commence PROACT 2 Phase 3 trial, and readout interim results from the ongoing REGEN-007 Phase 2 trial in mid-2024Strengthened leadership team with appointment of two key hires across Clinical and Technical OperationsEnded the first quarter with $329 million in cash and cash equivalents and marketable securities, su

      5/10/24 7:00:00 AM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

      WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. "We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential to preserve kidney function in patients with type 2 diabetes mellitus and advanced kidney disease, we look forward to the REGEN-007 Phase 2 interim data readout mid-year," said Bruce Culleton, Ch

      3/21/24 7:49:56 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PROK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $276,366 worth of Class A Ordinary Shares (387,393 units at $0.71) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/24/25 4:15:43 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $18,690 worth of Class A Ordinary Shares (25,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/21/25 4:37:34 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Control Empresarial De Capitales S.A. De C.V. bought $74,820 worth of Class A Ordinary Shares (100,000 units at $0.75) (SEC Form 4)

      4 - PROKIDNEY CORP. (0001850270) (Issuer)

      4/18/25 4:15:51 PM ET
      $PROK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care